《Table 1Clinical characteristics of study participants.》

  提示：宽带有限、当前游客访问压缩模式

本系列图表出处文件名：随高清版一同展现

《IL-37b suppresses epithelial mesenchymal transition in hepatocellular carcinoma by inhibiting IL-6/STAT3 signaling》

1. 获取 高清版本忘记账户？点击这里登录

1. 下载图表忘记账户？点击这里登录

CHB:chronic hepatitis B；HBV-HCC:HBV-related hepatocellular carcinoma；HBV-LC:HBV-related liver cirrhosis；ALT:alanine aminotransferase；AST:aspartate aminotransferase；AFP:alpha-fetoprotein.

Baseline characteristics of recruited subjects are shown in Table 1.Serum IL-37b was decreased in HBV-HCC and PVTT cases compared to healthy subjects（P<0.001；Fig.1 A and B）.Compared to HBV-HCC，serum IL-37b in patients with CHB and HBV-LC patients was significantly elevated（both P<0.001；Fig.1 A），there was no difference between CHB and HBV-LC groups（P=0.499；Fig.1 A）.The correlation between serum IL-37b and clinicopathological features of patients with HBV-HCC was shown in Table 2.Serum IL-37b was correlated with metastasis（P=0.033）and tumorstaging（P<0.001）.Kaplan-Meier analysis confirmed that subjects in the high IL-37b expression group had better overall survival（38.33 vs.28.93 months，P=0.031；Fig.1 C）and disease-free survival（33.53 vs.23.68 months，P=0.041；Fig.1 D）.